Cargando…

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting response to HMT remains an unresolved issue. We aimed to identify mutations associated with response to HMT and survival in MDS. A total of 107 Korean patients with MDS who und...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Seung-Hyun, Kim, Yoo-Jin, Yim, Seon-Hee, Kim, Hye-Jung, Kwon, Yong-Rim, Hur, Eun-Hye, Goo, Bon-Kwan, Choi, Yun-Suk, Lee, Sug Hyung, Chung, Yeun-Jun, Lee, Je-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342416/ https://www.ncbi.nlm.nih.gov/pubmed/27419369 http://dx.doi.org/10.18632/oncotarget.10526

Ejemplares similares

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5
por: Hur, Eun-Hye, et al.
Publicado: (2016)

Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome
por: Choi, Yunsuk, et al.
Publicado: (2019)

Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy
por: Kwon, Yong-Rim, et al.
Publicado: (2012)

Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells
por: Choi, Eun-Ji, et al.
Publicado: (2023)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Enhanced polo-like kinase 1 expression in myelodysplastic syndromes
por: Min, Kyoung Il, et al.
Publicado: (2019)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia
por: Choi, Eun-Ji, et al.
Publicado: (2021)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes
por: Kim, Kyuryung, et al.
Publicado: (2020)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas
por: Lim, Chul-Hyun, et al.
Publicado: (2016)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
por: Hur, Eun-Hye, et al.
Publicado: (2017)

A Case of Erythema Nodosum and Serositis Associated with Myelodysplastic Syndrome
por: Choi, Jung-Hye, et al.
Publicado: (2005)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis
por: Liu, Jieying, et al.
Publicado: (2018)

Long interspersed nuclear element-1 hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma
por: Lee, Yu Rim, et al.
Publicado: (2021)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations
por: Kim, Yoo-Jin, et al.
Publicado: (2013)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
por: Lee, Paul, et al.
Publicado: (2022)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Hypomethylation in the promoter region of ZPBP as a potential litter size indicator in Berkshire pigs
por: An, Sang Mi, et al.
Publicado: (2019)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party
por: Kim, Da Jung, et al.
Publicado: (2017)

Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia
por: Koo, Bon-Kwan, et al.
Publicado: (2022)

Somatic DNA Hypomethylation in H. pylori-Associated High-Risk Gastritis and Gastric Cancer: Enhanced Somatic Hypomethylation Associates with Advanced Stage Cancer
por: Leodolter, Andreas, et al.
Publicado: (2015)

Clinical Effects of Hypomethylating Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome Who Received DNA-Damaging Chemotherapy for Metastatic Breast Cancer
por: Baek, Dong Won, et al.
Publicado: (2019)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Pulmonary Leukocytoclastic Vasculitis as an Initial Presentation of Myelodysplastic Syndrome
por: Lee, Seung Hyun, et al.
Publicado: (2016)

Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations
por: Choi, Su-Hye, et al.
Publicado: (2017)

Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer
por: Jung, Chan Kwon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v8ovbm2uocdepttg86fmlhkqbr